Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression

Uptown Research Institute is excited to share that our mission of bringing science to practice has contributed to the success of the Phase 3 COMP360 psilocybin clinical research trial, led by Compass Pathways. The results of the study found that the investigational product, COMP360, demonstrated a statistically significant and clinically meaningful reduction of symptom severity in participants living with treatment-resistant depression. Congratulations to the hardworking people involved in achieving this milestone!

Click the link below to read the full news article:

Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression